FindTrial
Sign In

Evaluating Reduced Doses of Tofacitinib in Treating Axial Spondyloarthritis: A Multicenter Randomized Study

STRIDE-AS-Strategic tofacitinib dose reduction in axial spondyloarthritis:A multicentre randomized controlled assessor blinded,non inferiority trial - STRIDE-AS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/12/098992
Enrollment
180
Registered
2025-12-12
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M450- Ankylosing spondylitis of multiplesites in spine

Interventions

Intervention1: Tofactinib 5 mg TID: Randomly assigned 1:1 ratio and to continue standard-dose tofacitinib (5mg given twice daily) Control Intervention1: Tofacitinib 5 mg BD with 5 mgOD A/D(Tappering d

Sponsors

Dr Padmanabha Shenoy D
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adult patients aged 18 years to 50 years, with a diagnosis of radiographic axial spondyloarthritis

Exclusion criteria

Exclusion criteria:

Design outcomes

Secondary

MeasureTime frame
1.To compare the time to first flare between the two arms 2.To compare the change in ASDAS-CRP versus baseline at 32 weeks 3.To compare physical function and quality of life between the groups 4.To identify predictors of successful tapering Timepoint: 32 weeks—

Primary

MeasureTime frame
To evaluate whether a structured tapering strategy for tofacitinib is non-inferior to continued standard-dose tofacitinib (5mg twice daily) in sustaining flare-free remission at 16 weeks.Timepoint: 16 weeks—

Countries

India

Contacts

Public ContactDr Padmanabha Shenoy D

Sree Sudheendra Medical Mission

shiningsooraj@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026